The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis

Bone

Volumn 77, Issue , 2015, Pages 115-119

  Beck, Thomas J ^a   Fuerst, Thomas ^b   Gaither, Kenneth W ^b   Sutradhar, Santosh ^d   Levine, Amy B ^d   Hines, Teresa ^d   Yu, Ching Ray ^c   Williams, Robert ^c   Mirkin, Sebastian ^d   Chines, Arkadi A ^d  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b SYNARC INC   (United States)

^c PFIZER INC   (United States)

^d NONE

Author keywords

Bazedoxifene; Bone mineral density; Bone structural strength; Hip structure analysis; Postmenopausal osteoporosis; SERM

Indexed keywords

BAZEDOXIFENE; CALCIUM; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; BONE DENSITY CONSERVATION AGENT; INDOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE SCINTISCANNING; BONE STRENGTH; BONE STRUCTURE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FEMUR SHAFT; FRACTURE; HIP FRACTURE; HIP STRUCTURE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SCORING SYSTEM; SPINE FRACTURE; STRUCTURE ANALYSIS; VERY ELDERLY; BONE; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; AGED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; FEMALE; HUMANS; INDOLES; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS;

EID: 84928645411     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.04.027     Document Type: Article

References (31)

1. The North American Menopause Society Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:25-54.
2. U.S.Department of Health and Human Services The 2004 Surgeon General's Report on Bone Health and Osteoporosis: What It Means To You Accessed October 8, 2012. http://www.surgeongeneral.gov/library/reports/bonehealth/OsteoBrochure1mar05.pdf.
3. Colon-Emeric C., Kuchibhatla M., Pieper C., Hawkes W., Fredman L., Magaziner J., et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003, 14:879-883.
4. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
5. Uusi-Rasi K., Beck T.J., Semanick L.M., Daphtary M.M., Crans G.G., Desaiah D., et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 2006, 17:575-586.
6. Beck T.J., Ruff C.B., Scott W.W., Plato C.C., Tobin J.D., Quan C.A. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int 1992, 50:24-29.
7. Beck T.J., Stone K.L., Oreskovic T.L., Hochberg M.C., Nevitt M.C., Genant H.K., et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J Bone Miner Res 2001, 16:2103-2110.
8. Beck T.J., Lewiecki E.M., Miller P.D., Felsenberg D., Liu Y., Ding B., et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008, 11:351-359.
9. Bonnick S.L., Beck T.J., Cosman F., Hochberg M.C., Wang H., de Papp A.E. DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 2009, 20:911-921.
10. Chen Z., Beck T.J., Cauley J.A., Lewis C.E., LaCroix A., Bassford T., et al. Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the Women's Health Initiative hormone intervention trials. J Bone Miner Res 2008, 23:1935-1945.
11. Greenspan S.L., Beck T.J., Resnick N.M., Bhattacharya R., Parker R.A. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J Bone Miner Res 2005, 20:1525-1532.
12. Takada J., Miki T., Imanishi Y., Nakatsuka K., Wada H., Naka H., et al. Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis. J Bone Miner Metab 2010, 28:561-567.
13. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
14. Kaptoge S., Beck T.J., Reeve J., Stone K.L., Hillier T.A., Cauley J.A., et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 2008, 23:1892-1904.
15. LaCroix A.Z., Beck T.J., Cauley J.A., Lewis C.E., Bassford T., Jackson R., et al. Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density?. Osteoporos Int 2010, 21:919-929.
16. Imai K. Recent methods for assessing osteoporosis and fracture risk. Recent Pat Endocr, Metab Immune Drug Discov 2014, 8:48-59.
17. Miller P.D., Chines A.A., Christiansen C., Hoeck H.C., Kendler D.L., Lewiecki E.M., et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008, 23:525-535.
18. Silverman S.L., Christiansen C., Genant H.K., Vukicevic S., Zanchetta J.R., de Villiers T.J., et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923-1934.
19. Christiansen C., Chesnut C.H., Adachi J.D., Brown J.P., Fernandes C.E., Kung A.W., et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010, 11:130.
20. de Villiers T.J., Chines A.A., Palacios S., Lips P., Sawicki A.Z., Levine A.B., et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011, 22:567-576.
21. Palacios S., Silverman S.L., de Villiers T.J., Levine A.B., Goemaere S., Brown J.P., et al. A 7-year, randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture [published online ahead of print February 9, 2015]. Menopause 2015, 10.1097/GME.0000000000000419.
22. Palacios S., de Villiers T.J., Nardone F.C., Levine A.B., Williams R., Hines T., et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled phase 3 study. Maturitas 2013, 76:81-87.
23. Silverman S.L., Chines A.A., Kendler D.L., Kung A.W., Teglbjaerg C.S., Felsenberg D., et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012, 23:351-363.
24. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009, 44:1049-1054.
25. Kaufman J.M., Palacios S., Silverman S., Sutradhar S., Chines A. An evaluation of the Fracture Risk Assessment Tool (FRAX) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX. Osteoporos Int 2013, 24:2561-2569.
26. Kanis J.A., Oden A., Johansson H., Borgstrom F., Strom O., McCloskey E. FRAX and its applications to clinical practice. Bone 2009, 44:734-743.
27. Watts N.B., Ettinger B., LeBoff M.S. FRAX facts. J Bone Miner Res 2009, 24:975-979.
28. Watts N.B. The Fracture Risk Assessment Tool (FRAX(R)): applications in clinical practice. J Womens Health (Larchmt) 2011, 20:525-531.
29. Kanis J.A. Assessment of osteoporosis at the primary health-care level. Technical report 2007, on behalf of the World Health Organization Scientific Group, Sheffield, United Kingdom, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield.
30. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
31. Beck T.J. Extending DXA, beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 2007, 5:49-55.